ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Department of Justice Obtains $409 Million Settlement in Baron & Budd Whistleblower Lawsuit Against Rite Aid

The lawsuit is the first of its kind using the False Claims Act to bring a claim against a major retail pharmacy for its opioid dispensing practices.

Today, the nationally recognized law firm Baron & Budd announced the U.S. Department of Justice has obtained a settlement against Rite Aid in a groundbreaking lawsuit brought forth by whistleblowers alleging violations of the False Claims Act and the Controlled Substances Act. The whistleblowers in this case are former Rite Aid pharmacy employees represented by Baron & Budd. The settlement provides that the government will be paid $7.5 million and have an allowed, unsubordinated, general unsecured claim of $401.8 million in Rite Aid’s pending bankruptcy case.

According to the suit, the whistleblowers alleged that Rite Aid incentivized and pressured its pharmacists to fill all prescriptions – regardless of validity – which resulted in prescriptions that were not medically necessary being filled and billed to government programs.

Taxpayer-funded health care programs, such as Medicare, Medicaid, and Tricare, cover the costs of valid prescriptions issued for legitimate medical purposes, but these programs ended up paying out billions of dollars for medically unnecessary opioid prescriptions filled by Rite Aid pharmacies.

“We are pleased that our clients will be rewarded for their courage to come forward and expose the harmful practices of major retail pharmacies, like Rite Aid,” said Baron & Budd Shareholder Will Powers. “Millions of Americans have been impacted by the opioid epidemic resulting from the irresponsible operations of Rite Aid and other pharmacies.”

The suit alleged that Rite Aid had the data and information to enact safe and responsible opioid dispensing practices, but consistently disregarded its duties to properly identify, investigate, and resolve red flag prescriptions before dispensing. The settlement represents the first successful whistleblower case against a major pharmacy chain for its opioid-related conduct.

“Once again, we have successfully prosecuted a major corporation for fraud through the public/private partnership between the Department of Justice and whistleblowers,” said Baron & Budd shareholder Scott Simmer. “This should serve as a warning to retail pharmacies that the DOJ and whistleblowers will continue to work together to expose the destructive practices that endanger American lives and waste taxpayer dollars.”

Baron & Budd’s whistleblower representation team has more than 40 years of experience representing dozens of clients in government fraud cases. They have returned more than $6 billion to federal and state agencies with whistleblower recovery shares as high as 50%.

About Baron & Budd, P.C.

With more than 40 years of experience, Baron & Budd has the expertise and resources to handle complex litigation throughout the United States. As a law firm that takes pride in remaining at the forefront of litigation, Baron & Budd has spearheaded many significant cases for hundreds of public entities and tens of thousands of individuals. Since the firm was founded in 1977, Baron & Budd has achieved substantial national acclaim for its work on cutting-edge litigation, trying hundreds of cases to verdict and settling tens of thousands of cases in areas of litigation as diverse and significant as dangerous and highly addictive pharmaceuticals, defective medical devices, asbestos and mesothelioma, wildfires, environmental contamination, fraudulent banking practices, e-cigarettes, motor vehicles, federal whistleblower cases, and other consumer fraud issues.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.